We prospectively assessed patients' erectile function (EF) using the International Index of Erectile Function (IIEF) and a global assessment questionnaire (GAQ) following permanent 125I-brachytherapy for localized prostate cancer. Of 378 treated patients, 220 had a minimal 2-y follow-up and 131/220 were sexually active prior to brachytherapy, with an EF domain score of ≥11 (study group). Patients were allowed sildenafil at any time of the study. The patients' mean EF score, without excluding patients who used sildenafil, dropped within 3 months after brachytherapy, recovered at the end of the first year and remained unchanged for at least up to 2 y after treatment regardless of the addition of neoadjuvant hormone therapy to 125I-brachytherapy. Analysis of the GAQ revealed that 80% of the patients were satisfied with their sexual function up to 3 y after treatment. Any detrimental effect of permanent brachytherapy with or without the addition of hormone therapy on EF is reversible, and recovery is expected at 1 y after treatment in most patients.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $14.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Merrick GS, Butler WM, Lief JH, Dorsey AT . Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer? Tech Urol 2001; 7: 12–19.
Teloken C . Management of erectile dysfunction secondary to treatment for localized prostate cancer. Cancer Control 2001; 8: 540–545.
Stone NN, Stock RG . Complications following permanent prostate brachytherapy. Eur Urol 2002; 41: 427–433.
Stone NN, Stock RG . Permanent seed implantation for localized adenocarcinoma of the prostate. Curr Urol Rep 2002; 3: 201–206.
Woolsey J, Miller N, Theodorescu D . Permanent interstitial brachytherapy for prostate cancer: a current review. World J Urol 2003; 21: 209–219.
Merrick GS, Wallner KE, Butler WM . Management of sexual dysfunction after prostate brachytherapy. Oncology (Huntingt) 2003; 17: 52–62, (discussion 62, 67–70, 73).
Stock RG, Kao J, Stone NN . Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001; 165: 436–439.
Merrick GS et al. Short-term sexual function after prostate brachytherapy. Int J Cancer 2001; 96: 313–319.
Zelefsky MJ et al. Comparison of the 5-y outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999; 17: 517–522.
Merrick GS et al. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 52: 893–902.
Raina R et al. Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology 2003; 62: 1103–1108.
Merrick GS et al. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2001; 50: 597–604.
Merrick GS et al. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2000; 48: 1069–1074.
Fisch BM, Pickett B, Weinberg V, Roach M . Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology 2001; 57: 955–959.
Merrick GS et al. The importance of radiation doses to the penile bulb vs crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002; 54: 1055–1062.
DiBiase SJ, Wallner K, Tralins K, Sutlief S . Brachytherapy radiation doses to the neurovascular bundles. Int J Radiat Oncol Biol Phys 2000; 46: 1301–1307.
Kiteley RA et al. Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. Brachytherapy 2002; 1: 90–94.
Albert M et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer 2003; 98: 949–954.
Stipetich RL et al. Nursing assessment of sexual function following permanent prostate brachytherapy for patients with early-stage prostate cancer. Clin J Oncol Nurs 2002; 6: 271–274.
Merrick GS et al. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology 2002; 60: 104–108.
Incrocci L, Slob AK, Levendag PC . Sexual (dys)function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys 2002; 52: 681–693.
Montorsi F et al. Counselling the patient with prostate cancer about treatment-related erectile dysfunction. Curr Opin Urol 2001; 11: 611–617.
Matzkin H et al. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning. Urology 2003; 62: 497–502.
Matzkin H et al. Comparison between two iodine-125 brachytherapy implant techniques: pre-planning and intra-operative by various dosimetry quality indicators. Radiother Oncol 2003; 68: 289–294.
Bice Jr WS, Prestidge BR, Prete JJ, Dubois DF . Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using 125I. American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys 1998; 40: 1237–1241.
Hall JD, Boyd JC, Lippert MC, Theodorescu D . Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology 2003; 61: 402–407.
Beard CJ et al. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. J Clin Oncol 1997; 15: 223–229.
Turner SL, Adams K, Bull CA, Berry MP . Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Urology 1999; 54: 124–129.
Robinson JW, Moritz S, Fung T . Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002; 54: 1063–1068.
Krupski T, Petroni GR, Bissonette EA, Theodorescu D . Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology 2000; 55: 736–742.
Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D . Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer 2001; 91: 2046–2055.
Valicenti RK, Bissonette EA, Chen C, Theodorescu D . Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy. J Urol 2002; 168: 2499–2504, (discussion 2504).
Brandeis JM, Litwin MS, Burnison CM, Reiter RE . Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000; 163: 851–857.
Walsh PC . Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 1802–1807.
Walsh PC, Marschke P, Ricker D, Burnett AL . Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000; 55: 58–61.
Zippe CD et al. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998; 52: 963–966.
Lowentritt BH et al. Sildenafil citrate after radical retropubic prostatectomy. J Urol 1999; 162: 1614–1617.
Hong EK, Lepor H, McCullough AR . Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res 1999; 11 (Suppl 1): S15–S22.
Vale J . Erectile dysfunction following radical therapy for prostate cancer. Radiother Oncol 2000; 57: 301–305.
Zagaja GP, Mhoon DA, Aikens JE, Brendler CB . Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000; 56: 631–634.
Feng MI et al. Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction. J Urol 2000; 164: 1935–1938.
Raina R et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-y follow-up. Urology 2003; 62: 110–115.
We thank Esther Eshkol for editorial assistance.
About this article
Cite this article
Mabjeesh, N., Chen, J., Beri, A. et al. Sexual function after permanent 125I-brachytherapy for prostate cancer. Int J Impot Res 17, 96–101 (2005). https://doi.org/10.1038/sj.ijir.3901271
- erectile function
- prostate cancer